M. Hoffman, A cell-based model of coagulation and the role of factor VIIa, Blood Reviews, vol.17, pp.1-5, 2003.
DOI : 10.1016/S0268-960X(03)90000-2

D. Monroe and M. Hoffman, What Does It Take to Make the Perfect Clot?, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.26, issue.1, pp.41-49, 2006.
DOI : 10.1161/01.ATV.0000193624.28251.83

S. Butenas and K. Mann, Blood coagulation, Biochemistry (Moscow), vol.67, issue.1, pp.3-12, 2002.
DOI : 10.1023/A:1013985911759

J. Rau, L. Beaulieu, J. Huntington, and F. Church, Serpins in thrombosis, hemostasis and fibrinolysis, Journal of Thrombosis and Haemostasis, vol.262, issue.Suppl. 3, pp.102-117, 2007.
DOI : 10.1016/S1570-9639(03)00164-X

A. Vincenot and P. Gaussem, Physiologie et régulation cellulaire du système de la protéine C

M. Guillin, Physiologie de la coagulation

J. Griffin, J. Fernandez, A. Gale, and L. Mosnier, Activated protein C, Journal of Thrombosis and Haemostasis, vol.234, pp.73-80, 2007.
DOI : 10.4049/jimmunol.165.8.4697

D. Prost, D. Moatti, D. Petit, L. Ollivier, and V. , L'inhibiteur de la voie du facteur tissulaire (TFPI), molécule clé de défense contre la thrombose, Sang Thrombose Vaisseaux, vol.11, pp.548-554, 1999.

P. Sie and . Heparins, Principles and rules for their use . Dosage of nonfractionated heparins], Rev Prat, vol.48, pp.1361-1366, 1998.

P. Sandset, U. Abildgaard, and M. Larsen, Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI), Thrombosis Research, vol.50, issue.6, pp.803-816, 1988.
DOI : 10.1016/0049-3848(88)90340-4

B. Cosmi, J. Fredenburgh, J. Rischke, J. Hirsh, E. Young et al., Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate, Circulation, vol.95, issue.1, pp.118-142, 1997.
DOI : 10.1161/01.CIR.95.1.118

B. Boneu and F. Guerrero, Existe-t-il des différences entre les héparines de bas poids moléculaire ? San g Thrombose Vaisseaux, pp.6-10, 2006.

J. Hirsh and R. Raschke, Heparin and Low-Molecular-Weight Heparin, Chest, vol.126, issue.3, pp.188-203, 2004.
DOI : 10.1378/chest.126.3_suppl.188S

J. Wa-lenga, W. Jeske, L. Bara, M. Samama, and J. Fareed, BIOCHEMICAL AND PHARMACOLOGIC RATIONALE FOR THE DEVELOPMENT OF A SYNTHETIC HEPARIN PENTASACCHARIDE, Thrombosis Research, vol.86, issue.1, pp.1-36, 1997.
DOI : 10.1016/S0049-3848(97)00042-X

R. Wh-ite and J. Ginsberg, Low-Molecular-Weight Heparins: Are they all the Same?, British Journal of Haematology, vol.86, issue.1, pp.12-20, 2003.
DOI : 10.1302/0301-620X.82B6.9869

H. Bu-ller, G. Agnelli, R. Hull, T. Hyers, M. Prins et al., Antithrombotic Therapy for Venous Thromboembolic Disease, Chest, vol.126, issue.3, pp.401-428, 2004.
DOI : 10.1378/chest.126.3_suppl.401S

G. Nenci, Low molecular weight heparins: are they interchangeable? No, Journal of Thrombosis and Haemostasis, vol.86, issue.Suppl., pp.12-15, 2003.
DOI : 10.1016/S0049-3848(00)00272-3

URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1538-7836.2003.00017.x/pdf

P. Prandoni, Low molecular weight heparins: are they interchangeable? Yes, Journal of Thrombosis and Haemostasis, vol.100, issue.Suppl. 1, pp.10-11, 2003.
DOI : 10.1056/NEJM199204093261502

URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1538-7836.2003.00014.x/pdf

C. Cimminiello, Choice of low molecular weight heparins, Journal of Thrombosis and Haemostasis, vol.355, issue.3, pp.596-603, 2003.
DOI : 10.1016/S0140-6736(00)02324-2

A. Turpie, Choice of low molecular weight heparins, Journal of Thrombosis and Haemostasis, vol.40, issue.3, p.598, 2003.
DOI : 10.1016/S0735-1097(02)02336-7

M. Samama, Choice of low molecular weight heparins, Journal of Thrombosis and Haemostasis, vol.162, issue.3, pp.599-600, 2003.
DOI : 10.1001/archinte.162.16.1833

J. Fareed, W. Jeske, D. Hoppensteadt, R. Clarizio, and W. Lm, Low-molecular-weight heparins: pharmacologic profile and product differentiation, The American Journal of Cardiology, vol.82, issue.5, p.3, 199810.
DOI : 10.1016/S0002-9149(98)00105-2

J. Fareed and W. Lm, Why differentiate low molecular weight heparins for venous thromboembolism?, Thrombosis Journal, vol.5, issue.1, p.8, 2007.
DOI : 10.1186/1477-9560-5-8

A. Leizorovicz, L. Bara, M. Samama, and M. Haugh, Factor Xa Inhibition: Correlation between the Plasma Levels of Anti-Xa Activity and Occurrence of Thrombosis and Haemorrhage, Pathophysiology of Haemostasis and Thrombosis, vol.23, issue.1, pp.89-98, 1993.
DOI : 10.1159/000216915

E. Lindhoff-last, G. Mosch, and H. Breddin, Treatment doses of different low-molecular weight heparins and unfractioneated heparins differ in their anticoagulating effects in respect to aptt, hep test , anti-iia-and anti-xa-activity, Lab Med, vol.16, pp.174-177, 1992.

F. Depasse and M. Samama, Héparine non fractionnée et héparines de bas poids moléculaire, Samama MM et collaborateurs eds. H émorragies et thromboses. Du diagnostic au traitement Paris: Masson, pp.294-304, 2004.

B. Boneu, F. Nguyen, and C. Lp, Difficultés et pièges de la surveillance des traitements par l'héparine, Sang Thrombose Vaisseaux, vol.15, pp.131-135, 2003.

. Walenga-lm, W. Jeske, M. Samama, F. Frapaise, and R. Bick, Fareed 1. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent, Expert Opin Investig Drugs, vol.II, pp.397-407, 2002.

S. Beguin, The calibrated automated thrombogram (CAT): a universal routine test for hyperand hypocoagulability, Pathophysiol Haemost Thromb, vol.32, pp.249-53, 2002.

T. Baglin, The measurement and application of thrombin generation, British Journal of Haematology, vol.77, issue.5, pp.653-61, 2005.
DOI : 10.1046/j.1538-7836.2003.00450.x

T. Chapman and K. Goa, Bemiparin, Drugs, vol.88, issue.1, pp.2357-2377, 2003.
DOI : 10.2165/00003495-200363210-00009

G. Gerotziafas, A. Petropoulou, E. Verdy, and M. Samama, Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation, Journal of Thrombosis and Haemostasis, vol.69, issue.5, pp.955-62, 2007.
DOI : 10.1159/000073609

S. Petros, T. Siegemund, A. Siegemund, and L. Engelmann, The effect of different anticoagulants on thrombin generation, Blood Coagulation & Fibrinolysis, vol.17, issue.2, pp.131-137, 2006.
DOI : 10.1097/01.mbc.0000214708.73374.ce

A. Dieri, R. Alban, S. Beguin, S. Hemker, and H. , Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time, Journal of Thrombosis and Haemostasis, vol.71, issue.8, pp.1395-401, 2004.
DOI : 10.1080/00313020120062974

A. Padilla, E. Gray, O. Pepper, and T. Barrowcliffe, Inhibition of thrombin generation by heparin and 10w molecular weight (LMW) heparins in the absence and presence of platelet factor 4, Br J, vol.82, pp.406-413, 1992.

J. Walenga, L. Bara, D. Hoppensteadt, J. Choay, J. Fareed et al., ATiII as a rate limiting factor for the measurement of pentasaccharide in laboratory assays, Thromb Haemost, vol.65, p.1314, 1991.

B. Boneu, J. Necciari, C. Ou, R. Sié, P. Gabaig et al., Pharmacokinetics and tolerance of the natural pentasaccharide (SR90 107/0RG31540) with high affinity to antithrombin III in man, Thromb Haemost, vol.74, pp.1468-1473, 1995.

G. Gerotziafas, . Elalamy-1, F. Depasse, E. Perzbom, and M. Samama, In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban, Journal of Thrombosis and Haemostasis, vol.27, issue.4, pp.886-888, 2007.
DOI : 10.1111/j.1538-7836.2005.01657.x

N. Brufatto, A. Ward, and M. Nesheim, Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex, Journal of Thrombosis and Haemostasis, vol.36, issue.6, pp.1258-63, 2003.
DOI : 10.1021/bi970979+

T. Lindhout and H. He, Anticoagulant mechanism of actions of low molecular weight heparins In: Doutremepuich C ed. Low molecular weight heparins in clinical practice, pp.23-50, 1992.

A. Dieri, R. Alban, S. Beguin, S. Hemker, and H. , Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight, Journal of Thrombosis and Haemostasis, vol.122, issue.1, pp.83-92, 2006.
DOI : 10.1161/01.cir.0000089185.80318.3f

J. Oldenburg, C. Bevans, A. Fregin, C. Geisen, C. Muller-reible et al., Current phannacogenetic developments in oral anticoagulation therapy: The influence of variant VKORCI and CYP2C9 alleles, Thromb Haemost, vol.98, pp.570-578, 2007.

M. Rozalski, M. Bonder, B. Luzak, and C. Watala, Genetic factors underlying differential blood platelet sensitivity to inhibitors, Pharmacol Rep, vol.57, pp.1-13, 2005.

P. Fontana and J. Reny, Pharmacog??n??tique et m??dicaments antiplaquettaires, La Revue de M??decine Interne, vol.26, issue.9, pp.725-757, 2005.
DOI : 10.1016/j.revmed.2005.02.006

J. Fareed, W. Leong, D. Hoppensteadt, W. Jeske, J. Walenga et al., Development of Generic Low Molecular Weight Heparins: A Perspective, Hematology/Oncology Clinics of North America, vol.19, issue.1, pp.53-68, 2005.
DOI : 10.1016/j.hoc.2004.09.005